XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Subscribe To Our Newsletter & Stay Updated
